Drug-Coated Balloon Versus Drug-Eluting Stent for Treating De Novo Large Vessel Coronary Artery Disease: A Systematic Review and Meta-Analysis of 13 Studies Involving 2,888 Patients

Rodolfo Caminiti*, MD1,2; Giampiero Vizzari*, MD2; Alfonso Ielasi, MD1, Giampaolo Vetta,

MD^{2,3}; Antonio Parlavecchio, MD²; Domenico Giovanni Della Rocca, MD³; Carolina Montonati,

MD¹; Dario Pellegrini, MD¹; Mariano Pellicano, MD, PhD, MSc¹; Maurizio Tespili, MD¹; and

Antonio Micari, MD, PhD²

- 1. U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
- Cardiology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, UniversitairZiekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium.

* Doctors Caminiti and Vizzari contributed equally to this manuscript and joint first author

Declarations of interest: none

Acknowledgments: none

Word count: 2802

Funding statement: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability: The data underlying this article are available in the article and in its online supplementary material.

Address for Correspondence: Alfonso Ielasi, MD, FESC;

Unità Operativa di Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Via Belgioioso 173, 20157, Milan, Italy. e-mail: alielasi@hotmail.com

Abbreviations

- ACD: All cause death
- CAD: Coronary artery disease
- CI: Confidence interval
- CVD: Cardiovascular death
- DAPT: Dual antiplatelet therapy
- DCB: Drug-coated balloon
- **DES:** Drug-eluting stent
- **ISR:** In-stent restenosis
- LV: Large vessel
- MACE: Major adverse cardiovascular events
- MD: Mean difference
- MI: Myocardial infarction
- MLD: Minimal lumen diameter
- PCB: Paclitaxel coated balloon
- PCI: Percutaneous coronary intervention
- PRISMA: Preferred reporting items for systematic reviews and meta-analyses
- QCA: Quantitative coronary analysis
- RR: Risk ratio
- SCB: Sirolimus coated balloon
- SVD: Small vessel disease
- TLF: Target lesion failure
- TLR: Target lesion revascularization
- ULM: Unprotected left main

Abstract

Introduction: Drug-coated balloon (DCB) is an established treatment option for in-stent restenosis and small vessel, de novo, coronary artery disease (CAD). Although the use of this tool is increasing in everyday practice, little is known about its performance in the treatment of de novo, large vessel CAD (LV-CAD). A systematic review and meta-analysis were conducted to evaluate the efficacy and safety of DCB versus drug-eluting stent (DES) in this setting.

Methods: A comprehensive literature search was performed including Medline, Embase and Cochrane electronic databases up to October 24th 2023, for studies which compared efficacy and safety of DCB versus DES in the treatment of de novo lesions in large vessels (> 2.5 mm), reporting clinical least one outcome of interest (PROSPERO ID: CRD42023470417). at The outcomes analysed were cardiovascular death (CVD), myocardial infarction (MI), target lesion revascularization (TLR), all cause death (ACD) and late lumen loss (LLL) at follow-up. The effect size was estimated using a random-effect model as risk ratio (RR) and mean difference (MD) and relative 95% confidence interval (CI).

Results: A total of 13 studies (6 randomized controlled trials and 7 observational studies) involving 2,888 patients (DCB n=1,334; DES n=1,533) with de novo LV-CAD were included in this metaanalysis following our inclusion criteria. A DCB-only strategy was non inferior to percutaneous coronary intervention (PCI) with DES in terms of CVD (RR 0.49; 95% CI [0.23 - 1.03]; p=0.06), MI (RR 0.48; 95% CI [0.16 - 1.45]; p=0.89), TLR (RR 0.73; 95% CI [0.40 - 1.34]; p=0.32), ACD (RR 0.78; 95% CI [0.57 - 1.07]; p=0.12) and LLL (MD -0.14; 95% CI [-0.30 - 0.02]; p=0.18) at follow-up.

Conclusion: Our meta-analysis showed that DCB PCI might provide a promising option for the management of selected, de novo LV-CAD compared to DES. However, more focused RCTs are needed to further prove the benefits of a "metal free" strategy in this subset of CAD.

Keywords

Drug-coated balloon, drug-eluting stent, de novo, coronary artery disease, large vessel disease,

angioplasty

Introduction

Drug-eluting stent (DES) implantation represents the gold-standard treatment strategy for de novo CAD.¹ However, DES are still associated with a non negligible rate of target lesion failure (TLF) at follow-up mainly due to device-related phenomena (e.g. polymer associated inflammation of the vessel wall, poor/excessive endothelialisation, incomplete stent expansion/apposition).^{2,3} In this scenario, drug-coated balloon (DCB) is emerging as a fashionable alternative to lower total stent length during PCI while preserving the anatomy and physiology of the vessel wall. A proper lesion preparation is paramount to achieve an optimal DCB PCI in order to avoid acute recoil and favour the correct penetration of the drug inside the vessel wall.⁴ Current European Guidelines recommend DCB PCI for the treatment of in-stent restenosis (ISR) with a class IA recommendation, while many clinical trials, observational studies and meta-analysis confirm its efficacy and safety in the treatment of de novo, small vessel disease (SVD).⁵⁻⁷ DCB PCI may also be considered a viable option in specific settings (e.g. high bleeding risk patients) or in association with DES in case of diffuse (e.g. CAD SVD.⁸⁻¹⁰ lesion/true bifurcation) long involving Although DCBs use for the treatment of de novo CAD is rapidly increasing, very little is known about the performance of a "metal free" approach for treating de novo large-vessel CAD (LV-CAD). The aim of this meta-analysis is to evaluate the efficacy and safety of DCBs compared with DES in this setting of CAD.

Methods

Data Sources and Searches

We systematically searched the Medline, Embase, and Scopus electronic databases for studies published until 24th October 2023, focusing on those comparing the efficacy and safety of DCB and DES in the treatment of de novo LV-CAD with a reference vessel diameter (RVD) \geq 2.5 mm and

reporting at least one clinical outcome of interest. Two investigators (R.C. and G.V.) independently conducted searches using the following terms: "drug eluting stent", "drug coated balloon", "myocardial infarction". Detailed information on our literature search strategy is available in the Supplementary Appendix in the Expanded Methods.

Study Selection

The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement for reporting systematic reviews meta-analyses used this study. and in was The predefined protocol was registered to the international prospective registry of systematic reviews (POSPERO ID: CRD42023470417). Studies had to meet the following criteria in order to be included in the analysis: (1) adult (\geq 18 years) population; 2) direct comparison between DCB and DES, (3) \geq 6 months clinical and/or angiographic follow-up available; (4) one or more clinical outcomes of interest reported (e.g., cardiovascular death myocardial infarction, all-cause death). Case reports, editorials, reviews, expert opinions, and studies not published in English language were excluded.

Data Extraction and Quality Appraisal

Two investigators (R.C and G.V) extracted data from each trial using standardised protocol and reporting forms. Two reviewers (R.C and G.V) independently assessed quality items and disagreements were resolved by consensus. The Newcastle-Ottawa Quality Assessment Scale for cohort studies and the Cochrane Risk of Bias Tool for randomised clinical trials (RCTs) were used by two investigators (R.C and G.V) to assess the quality of each study.

Study Endpoints

Cardiovascular death (CVD) was defined as death resulting from cardiovascular causes. Myocardial infarction (MI) was defined based on the fourth universal definition of PCI-Related MI \leq 48 hours after the index procedure (Type 4a MI).¹¹ Target lesion revascularization (TLR) was defined as a repeat PCI within the stented or DCB-treated segment or bypass surgery of the target vessel

performed for restenosis or other complication of the target lesion. All cause death (ACD) was defined as death resulting from cardiovascular and other causes. The angiographic endpoint was late lumen loss (LLL) obtained by quantitative coronary angiography (QCA) and defined as minimal lumen diameter (MLD) immediately after PCI minus MLD at follow-up angiography. All endpoints were commonly defined according to the Academic Research Consortium definitions.¹²

Statistical Analysis

Descriptive statistics are presented as mean and standard deviation (SD) for continuous variables, or number of cases (n) and percentage (%) for dichotomous and categorical variables. The Mantel-Haenszel risk ratio (RR) model was used to summarize the data for binary outcomes between treatment arms. For continuous variables, summary estimates and 95% confidence intervals (CI) were reported as the standardised mean difference. Heterogeneity between studies was assessed using the Chi2, Tau2 and Higgins-I2 statistics, and random effects models by DerSimonian and Laird were used. Subgroup analyses were performed including only RCTs.

Publication bias was assessed using funnel plots. Statistical analysis was performed with Review Manager (RevMan) (computer program) version 5.4.1, Copenhagen, Denmark: Nordic Cochrane Centre, The Cochrane Collaboration, 2020

Results

Study Selection and Baseline Characteristics

Among 597 screened articles, 53 full texts were retrieved and reviewed for possible inclusion; a total of 13 studies fulfilled the selection criteria and were included in the final analysis (**Figure 1**). The studies enrolled n=2,888 patients (Group DCB, n=1,334 patients; Group DES, n=1,533 patients). Overall, 75.3% (95% CI: 71.3 – 79.4%) patients were male with an average age of 63.2 years (95% CI: 57.3 - 70.5). The indication for revascularization was in 60.2% (95% CI: 38.7 –

85.1%) of cases acute coronary syndrome (ACS). The left anterior descending (LAD) artery was treated in the majority of cases (47.1%; 95% CI: 35.8 - 57.9%), followed by the right coronary artery (25.5%; 95% CI: 19.9 – 33.7%), left circumflex artery (18.1%; 95% CI: 11.5 – 23.3%) and unprotected left main (ULM) (9.3%; 95% CI: 6.1 – 23.2%).

The mean lesion length was 22.8 mm (95% CI: 15.3 - 40.2 mm) in the DCB and 27.9 mm (95% CI: 18.1 - 45.6 mm) in the DES group. The mean reference vessel diameter (RVD) was 3.14 mm (95% CI: 2.79 – 3.32 mm) in the DCB and 3.18 mm (95% CI: 2.69 – 3.57 mm) in the DES group. All studies used paclitaxel coated balloons (PCB) except one in which sirolimus coated balloon (SCB) was also used.

Further details on baseline characteristics, clinical and angiographic follow-up time of the studies population are reported in **Table 1**.

Endpoints

Twelve studies reported clinical follow-up data on CVD, MI and TLR.^{13–24} No differences were found between DCB and DES for the risk of CVD [1.1% vs 3.2%; RR: 0.49 (95% CI: 0.23 - 1.03; p=0.06; $I^2=0\%$] (**Figure 2**); MI [0.3% vs 1.5%; RR: 0.48 (95% CI: 0.16 - 1.45; p=0.89; $I^2=0\%$] (**Figure 3**), and TLR [3.7% vs 6.1%; RR: 0.73 (95% CI: 0.40 - 1.34; p=0.32; $I^2=27\%$] (**Figure 4**). Eight studies reported data on ACD^{14,16–20,24,25}. At follow-up, no differences were found between DCB and DES for the risk of ACD [5.5% vs 7.8%; RR: 0.78 (95% CI: 0.57 - 1.07; p=0.12; $I^2=0\%$] (**Figure 5**).

In terms of angiographic results, nine studies reported data on LLL.^{13,15–19,21–23} DCB was not inferior to DES for LLL at follow-up [MD: -0.14 (95% CI: -0.30 - 0.02; p=0.10; I²=91%] (**Figure 6**). Finally, six studies reported data on MLD before and after PCI.^{15–19,23} DES proved a higher mean acute gain versus DCB [1.94 (1.73, 2.14) vs 1.31 (1.02, 1.60); p=0.0006; I² 91.6%] (**Figure 7**).

Subgroup analysis including only RCTs

Six RCTs reported data on CVD, MI and TLR.^{13,19–23} At follow-up, no differences were found between DCB and DES for the risk of CVD [1.2% vs 0.9%; RR: 0.84 (95% CI: 0.21-3.40; p=0.80; $I^2=0\%$] (**Figure 8A**), MI [0.9% vs 1.6%; RR: 0.64 (95% CI: 0.18-2.30; p=0.49; I²=0%] (**Figure 8B**) and TLR [1.5% vs 2.3%; RR: 0.77 (95% CI: 0.24-2.50; p=0.67; I²=0%] were found (**Figure 8C**). Two RCTs reported data on ACD.^{19,20} No differences were found between DCB and DES for the risk of ACD at follow-up [3.5% vs 4.7%; RR: 0.60 (95% CI: 0.16-2.30; p=0.46; I²=0%] (**Figure 8D**).

Six RCTs studies reported data on LLL.^{13,19,21–23} No differences were observed between DCB and DES for LLL at follow up [MD: -0.08 (95% CI: -0.27 - 0.12; p=0.44; I²=91%] (**Figure 8E**). Two RCTs studies reported data on MLD before and after the procedure.^{19,23} DES proved a higher MLD mean difference before and after PCI [1.79 (1.67, 1.91) vs 1.06 (0.94, 1.18); p<0.00001; I^2 =98.6%] (**Figure 9**).

Publication Bias

A graph and summary of Cochrane Risk of Bias tool for RCTs and Newcastle–Ottawa Quality Assessment Scale for cohort studies is reported in **Supplemental Figure 1**. The funnel plots for visual inspection of the bias showed no bias (**Supplemental Figure 2**).

Discussion

In this meta-analysis, we evaluated the role of a "metal-free" approach with DCB for the treatment of de novo LV-CAD in both, acute and elective settings.

In summary, our results suggest that the usage of DCB-only strategy in this scenario is safe and effective with similar clinical and angiographic results compared to DES. The feasibility of treating LV-CAD with a DCB was initially established in retrospective and prospective observational registries.^{26–28}

Several RCTs assessed the role of a "metal free" approach vs. DES PCI in selected de novo lesions (e.g. "culprit", heavily calcified and ULM) located in large vessels. Consistently with other studies, our analysis confirmed that, in LV-CAD PCI, DES is associated with a significantly higher acute gain as compared to DCB (1.94 mm vs 1.31 mm; p=0.0006). However, LLL at follow-up was similar between the devices, claiming for a positive remodelling related to DCB PCI.^{4,5,29,30}

In a sub-analysis of the DEB-AMI trial, Nijhoff et al demonstrated the feasibility of a DCB-only PCI (n=40) in ACS with large target vessel disease (average RVD: 2.83 ± 0.51 mm, lesion length: 13.0 ± 5.7 mm, DCB diameter: 3.3 ± 0.4 mm). Despite the higher LLL at 12-month follow-up in the DCB arm (0.51 ± 0.59 mm vs. 0.21 ± 0.32 mm, p<0.01), no differences in ACD, target-vessel revascularization (TVR), TLR, MI were reported as compared to DES.¹⁸

The first randomized head-to-head comparison of DCB vs. DES in STEMI patient with LV-CAD (average RVD 2.61 \pm 0.49 mm DCB group, 3.04 \pm 0.46 mm DES group) reported comparable LLL and major adverse cardiovascular events (MACE: a composite of CVD, re-MI, TLR, and stent thrombosis) rate at 6-month follow-up between the groups (LLL 0.10 \pm 0.19 mm DES vs. -0.09 \pm 0.09 DCB, p<0.05).¹³

The REVELATION trial evaluated the performance of a DCB-only PCI in STEMI patients (n=120) undergoing primary PCI on a large culprit vessel (average RVD 3.28 ± 0.52 mm DCB group, 3.20 ± 0.48 mm DES group). Primary end-point was the fractional flow reverse (FFR) value at the end of the procedure and at 9-month follow-up. No major adverse events occurred at follow-up and the

angiographic/functional outcomes were similar between the two groups (mean FFR 0.92 ± 0.05 DCB vs. 0.91 ± 0.06 DES, p=0.27; mean LLL -0.05 ± 0.46 mm DCB vs. -0.02 ± 0.2 mm DES, p=0.51).²¹

The PEPCAD NSTEMI trial randomized 210 patients comparing DCB vs. stent [bare metal stent (BMS) and DES] in de novo, non-thrombus containing LV-culprit lesions (RVD as inclusion criteria: 2.5-3.5 mm). No differences were found between the groups in terms of CVD/ACD, re-MI, and TLR at 9-month follow-up (DCB: 4.7% vs. DES: 5.9%, p<0.88).²⁰

An interesting point arising from these studies relates to the usage of DCB PCI in "culprit" lesions, which are not considered a good spot for a metal-free approach because of the potentially lower dose of drug transferred to the vessel wall, particularly in thrombus containing lesions. Indeed, the sub-analysis of the DEB-AMI trial showed a higher LLL in the DCB arm. However, this result might have been influenced by the DCB used (the first generation DIOR delivers 25% only of the drug dose to the vessel wall).³¹

DCB PCI was also challenged vs. DES in heavily calcified lesions requiring rotational atherectomy (average RVD 2.97 \pm 0.45 mm, lesion length 14.3 \pm 7.3 mm DCB group; average RVD 3.03 \pm 0.36 mm, lesion length 19 \pm 10 mm DES group). Angiographic and clinical outcomes at 1-year follow-up (LLL 0.29 \pm 0.60 mm DES vs. 0.31 \pm 0.67 mm DCB, p=0.83; MACE 8% DES vs. 11% DCB, p=0.30) were similar between the groups.¹⁶

Even in de novo ULM disease (average RVD 3.84 ± 0.26 mm, lesion length: 21.71 ± 7.80 mm DCB group; average RVD 4.33 ± 0.60 mm, lesion length 24.72 ± 14.32 mm DES group) DCB PCI was associated with similar results as compare to DES [TLR: 7.3% DCB vs. 8.3% DES (HR: 0.89 (0.24–3.30), p=0.86)] at a median of 33 months follow-up.¹⁴

More recently, a propensity score (PS) matching analysis of a DCB-alone or in combination with DES ("hybrid" strategy) versus a DES-alone strategy (n=139 pairs) in the treatment of de novo long LAD lesions (mean RVD 3.14 ± 0.40 mm, lesion length 56.87 ± 16.7 mm) resulted in a lower TLF rate (TLR, CVD, and target vessel-MI) at 2 years in the DCB group as compared to the DES

group (5.9% DES vs. 0% DCB). Furthermore, a signal toward lower CVD risk was reported in the DCB group. This finding is consistent with the results of our meta-analysis, where this outcome is close to significance (p=0.06), hypothesizing an advantage of the "metal-free" approach.²⁴ Looking at technical aspects, pre-dilation was mandatory in all treatment groups. This manoeuvre is a key step for a successful PCI, particularly in case of DCB usage. According to the DCB consensus group, an optimal lesion preparation (e.g. residual % diameter stenosis less than 30) is required prior to DCB inflation.³² An "aggressive" (e.g., non-compliant -NC- balloons escalation to super high-pressure NC balloons, scoring/cutting balloons, intravascular lithotripsy, debulking devices) pre-dilatation strategy could facilitate plaque incision and drug transfer to the vessel wall, reducing elastic recoil and influencing a good clinical outcome.⁴

Even in ACS setting and in presence of thrombus, optimal lesion preparation is mandatory before inflating a DCB. Proper thrombus aspiration, which was performed in many of the ACS patients enrolled in the above studies (78% in the DCB group of the REVELATION Trial), could be crucial to reduce the number of pre-dilatation balloon inflations and the subsequent risk of distal embolization while facilitating drug penetration in the vessel wall.

Although vessel preparation plays a key role in DCB PCI, on the other hand may be associated with vessel injuries. Indeed, a main concern associated with DCB-PCI-only in proximal LV-CAD is the occurrence of malignant dissections. Cortese et al. assessed the fate of leaving non-flow-limiting dissection (A-C) after DCB PCI. At 6-month angiographic follow-up complete vessel healing was reported in 93.8% of cases while a low incidence of major adverse events occurred at 9-month follow-up (7.2% no-dissection cohort vs. 8.1% dissection cohort; p=0.48). The authors hypothesised that paclitaxel may play a role in facilitating coronary vessel healing when properly delivered at the target site.³³ Beside to angiography, a functional evaluation could lead the management of a dissection in the setting of DCB PCI. Especially in case of type A-B dissection, a Pd/Pa threshold of more or equal than 0.90 may be used as a surrogate for optimal outcome (leaving

the dissection) while a Pd/Pa less than 0.90 may lead to bail-out DES implantation reducing the risk of abrupt vessel closure and MI.³⁴

Of note, most of the studies included in this meta-analysis assessed the performance of PCBs, with the most commonly used brand being Sequent Please (B. Braun) in seven studies.

The main difference among PCBs is related to the formulation of the water-soluble excipient and the drug concentration, with the first aspect mostly influencing the final effect on the vessel wall, due to its sustained release properties. Although a non-randomised, score-matched comparison (SIRPAC trial) of two large registries assessing the performance of a PCB (Elutax SV, Aachen Resonance, Lainate, Italy) versus a first generation SCB (Magic Touch, Concept Medical, Tampa, Florida, USA) reported similar clinical results at 12 months^{35–37}, a recent randomized study showed that the same SCB resulted inferior to SeQuent Please Neo PCB in terms of angiographic net lumen gain at 6 months (lumen gain 0.25 ± 0.40 mm SCB, 0.48 ± 0.37 mm PCB).³⁸ These results deserve further attention particularly when choosing a DCB in the setting of LV-CAD.

Last but not least, the studies included in this meta-analysis are mainly related to selected lesions (length in both arms less than 28 mm) in specific subsets (e.g. calcified, ULM and ACSs), which are currently considered "off-label" for DCBs usage. Despite that, our results showed encouraging outcomes associated with the "metal-free" approach. Data from ongoing RCTs comparing current generation DCBs vs. DES in large cohort of patients including those with LV-CAD are awaited.^{39,40}

Limitations

Main limitation of our meta-analysis is the inclusion of observational studies beside to RCTs, which might limit the strengthens of the study. However, our results were confirmed at the subgroup analysis of RCTs only.

Conclusions

DCBs are an attractive option for the treatment of de novo CAD. Our meta-analysis showed no significant clinical and angiographic differences between DCB and DES in treating LV-CAD in either acute or elective settings. Focused RCTs providing further evidence on the potential benefit of a metal free approach in LV-CAD are strongly needed.

References

1. Colombo A, Iakovou I. Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation. European Heart Journal. 2004;25:895-897.

2. Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, Benedetto U, Biondi-Zoccai G, Smits PC, von Birgelen C, Mehran R, McAndrew T, Serruys PW, Leon MB, Pocock SJ, Stone GW. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2020;75:590-604.

3. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2013;6:1263-1266.

4. Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin E-S, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC: Cardiovascular Interventions. 2020;13:1391–1402.

5. Latib A, Ruparelia N, Menozzi A, Castriota F, Micari A, Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P, Sgueglia GA, Buffoli F, Tamburino C, Varbella F, Colombo A. 3-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study (BELLO). JACC Cardiovasc Interv. 2015;8:1132-1134.

6. Jeger RV, Farah A, Ohlow M-A, Mangner N, Möbius-Winkler S, Weilenmann D, Wöhrle J, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Osswald S, Cattaneo M, Gilgen N, Kaiser C, Scheller B, BASKET-SMALL 2 Investigators. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020;396:1504–1510.

7. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F-J, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-2619.

8. Ielasi A, Buono A, Pellicano M, Tedeschi D, Loffi M, Donahue M, Regazzoli D, De Angelis G, Danzi G, Reimers B, Tespili M. A HYbrid APproach Evaluating a DRug-Coated Balloon in Combination With a New-Generation Drug-Eluting Stent in the Treatment of De Novo Diffuse Coronary Artery Disease: The HYPER Pilot Study. Cardiovasc Revasc Med. 2021;28:14-19.

9. Rissanen TT, Uskela S, Eränen J, Mäntylä P, Olli A, Romppanen H, Siljander A, Pietilä M, Minkkinen MJ, Tervo J, Kärkkäinen JM, Vatanen A, Perälä A, Müller M, Porela P, Palojoki E. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. The Lancet. 2019;394:230-239.

10. Buono A, Pellicano M, Regazzoli D, Donahue M, Tedeschi D, Loffi M, Zimbardo G,

Reimers B, Danzi G, DE Blasio G, Tespili M, Ielasi A. Procedural and one-year outcomes following drug-eluting stent and drug-coated balloon combination for the treatment of de novo diffuse coronary artery disease: the HYPER Study. *Minerva Cardiol Angiol*. 2023. doi:10.23736/S2724-5683.23.06352-4.

11. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, null null. Fourth Universal Definition of Myocardial Infarction (2018). *Circulation*. 2018;138:e618–e651.

12. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel M-A, van Es G-A, Zuckerman B, Fearon WF, Taggart D, Kappetein A-P, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW, Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *Eur Heart J.* 2018;39:2192–2207.

13. Gobić D, Tomulić V, Lulić D, Židan D, Brusich S, Jakljević T, Zaputović L. Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: A Feasibility Study. *The American Journal of the Medical Sciences*. 2017;354:553–560.

14. Gunawardena TD, Corballis N, Merinopoulos I, Wickramarachchi U, Reinhold J, Maart C, Sreekumar S, Sawh C, Wistow T, Sarev T, Ryding A, Gilbert TJ, Clark A, Vassiliou VS, Eccleshall S. Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study. *Journal of Cardiovascular Development and Disease*. 2023;10:84.

15. Her A-Y, Shin E-S, Lee JM, Garg S, Doh J-H, Nam C-W, Koo B-K. Paclitaxel-coated balloon treatment for functionally nonsignificant residual coronary lesions after balloon angioplasty. *Int J Cardiovasc Imaging*. 2018;34:1339–1347.

16. Iwasaki Y, Koike J, Ko T, Funatsu A, Kobayashi T, Ikeda T, Nakamura S. Comparison of drug-eluting stents vs. drug-coated balloon after rotational atherectomy for severely calcified lesions of nonsmall vessels. *Heart Vessels*. 2021;36:189–199.

17. Nakamura H, Ishikawa T, Mizutani Y, Yamada K, Ukaji T, Kondo Y, Shimura M, Aoki H, Hisauchi I, Itabashi Y, Nakahara S, Kobayashi S, Taguchi I. Clinical and Angiographic Outcomes of Elective Paclitaxel-Coated Balloon Angioplasty in Comparison with Drug-Eluting Stents for De Novo Coronary Lesions in Large Vessels. *Int Heart J*. 2023;64:145–153.

18. Nijhoff F, Agostoni P, Belkacemi A, Nathoe HM, Voskuil M, Samim M, Doevendans PA, Stella PR. Primary percutaneous coronary intervention by drug-eluting balloon angioplasty: The nonrandomized fourth arm of the DEB-AMI (drug-eluting balloon in ST-segment elevation myocardial infarction) trial. *Catheterization and Cardiovascular Interventions*. 2015;86:S34–S44.

19. Nishiyama N, Komatsu T, Kuroyanagi T, Fujikake A, Komatsu S, Nakamura H, Yamada K, Nakahara S, Kobayashi S, Taguchi I. Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease. *International Journal of Cardiology*. 2016;222:113–118.

20. Scheller B, Ohlow M-A, Ewen S, Kische S, Rudolph T, Clever Y, Wagner A, Richter S, El-Garhy M, Böhm M, Degenhardt R, Mahfoud F, Lauer B. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. doi:10.4244/EIJ-D-19-00723.

21. Vos NS, Fagel ND, Amoroso G, Herrman J-PR, Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T, Vink MA. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in

Acute Myocardial Infarction: The REVELATION Randomized Trial. *JACC: Cardiovascular Interventions*. 2019;12:1691–1699.

22. Hao X, Huang D, Wang Z, Zhang J, Liu H, Lu Y. Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. *Journal of Cardiothoracic Surgery*. 2021;16:178.

23. Yu X, Wang X, Ji F, Zhang W, Yang C, Xu F, Wang F. A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions. *Cardiovasc Drugs Ther*. 2022;36:655–664.

24. Gitto M, Sticchi A, Chiarito M, Novelli L, Leone PP, Mincione G, Oliva A, Condello F, Rossi ML, Regazzoli D, Gasparini G, Cozzi O, Stefanini GG, Condorelli G, Reimers B, Mangieri A, Colombo A. Drug-Coated Balloon Angioplasty for De Novo Lesions on the Left Anterior Descending Artery. *Circulation: Cardiovascular Interventions.*;0:e013232.

25. Merinopoulos I, Gunawardena T, Corballis N, Bhalraam U, Gilbert T, Maart C, Richardson P, Ryding A, Sarev T, Sawh C, Sulfi S, Wickramarachchi U, Wistow T, Mohamed MO, Mamas MA, Vassiliou VS, Eccleshall SC. Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice. *Clin Res Cardiol.* 2023;112:1186–1193.

26. Rosenberg M, Waliszewski M, Chin K, Ahmad WAW, Caramanno G, Milazzo D, Nuruddin AA, Liew HB, Maskon O, Aubry P, Poyet R, Frey N. Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary lesions: The DCB-only All-Comers Registry. *Catheterization and Cardiovascular Interventions*. 2019;93:181–188.

27. Toelg R, Merkely B, Erglis A, Hoffmann S, Bruno H, Kornowski R, Slagboom T, Naber C, Witzenbichler B, Graf K, Richardt G, Hehrlein C. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry. EuroIntervention. doi:10.4244/EIJV10I5A102.

28. Venetsanos D, Lawesson SS, Panayi G, Tödt T, Berglund U, Swahn E, Alfredsson J. Longterm efficacy of drug coated balloons compared with new generation drug-eluting stents for the treatment of de novo coronary artery lesions. *Catheterization and Cardiovascular Interventions*. 2018;92:E317–E326.

29. Cortese B, Di Palma G, Guimaraes MG, Piraino D, Orrego PS, Buccheri D, Rivero F, Perotto A, Zambelli G, Alfonso F. Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial. *JACC: Cardiovascular Interventions*. 2020;13:2840–2849.

30. Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*. 2020;75:1061–1073.

31. Pósa A, Nyolczas N, Hemetsberger R, Pavo N, Petnehazy Ö, Petrasi Z, Sangiorgi G, Gyöngyösi M. Optimization of drug-eluting balloon use for safety and efficacy: Evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. *Catheterization and Cardiovascular Interventions*. 2010;76:395–403.

32. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wöhrle J, Jeger R, Levenson B, Möbius-Winkler S, Bruch L, Fischer D, Hengstenberg C, Pörner T, Mathey D, Scheller B. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. *Clin Res Cardiol*. 2013;102:785–797.

33. Cortese B, Silva Orrego P, Agostoni P, Buccheri D, Piraino D, Andolina G, Seregni RG. Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection. *JACC Cardiovasc Interv.* 2015;8:2003–2009.

34. Leone PP, Mangieri A, Regazzoli D, Laricchia A, Khokhar A, Rossi ML, Latib A, Reimers B, Colombo A. Drug-Coated Balloon Angioplasty Guided by Postpercutaneous Coronary Intervention Pressure Gradient: The REDUCE-STENT Retrospective Registry. *JACC Cardiovasc Interv*. 2023;16:363–365.

35. Cortese B, Caiazzo G, Di Palma G, De Rosa S. Comparison Between Sirolimus- and Paclitaxel-Coated Balloon for Revascularization of Coronary Arteries: The SIRPAC (SIRolimus-PAClitaxel) Study. *Cardiovascular Revascularization Medicine*. 2021;28:1–6.

36. Cortese B, Testa L, Heang TM, Ielasi A, Bossi I, Latini RA, Lee CY, Perez IS, Milazzo D, Caiazzo G, Tomai F, Benincasa S, Nuruddin AA, Stefanini G, Buccheri D, Seresini G, Singh R, Karavolias G, Cacucci M, Sciahbasi A, Ocaranza R, Menown IBA, Torres A, Sengottvelu G, Zanetti A, Pesenti N, Colombo A, EASTBOURNE Investigators. Sirolimus-Coated Balloon in an All-Comer Population of Coronary Artery Disease Patients: The EASTBOURNE Prospective Registry. *JACC Cardiovasc Interv*. 2023;16:1794–1803.

37. Cortese B, D'Ascenzo F, Fetiveau R, Balian V, Blengino S, Fineschi M, Rogacka R, Lettieri C, Pavei A, D'Amico M, Poli A, Di Palma G, Latini RA, Orrego PS, Seregni R. Treatment of coronary artery disease with a new-generation drug-coated balloon: final results of the Italian Elutax SV rEgistry-DCB-RISE. *J Cardiovasc Med (Hagerstown)*. 2018;19:247–252.

38. Ninomiya K, Serruys PW, Colombo A, Reimers B, Basavarajaiah S, Sharif F, Testa L, Di MC, Nerla R, Ding D, Huang J, Kotoku N, Kageyama S, Kageyama M, Sevestre E, Fezzi S, Dijkstra J, O 'Leary Neil, Morel MA, Garg S, Cortese B, Onuma Y. A Prospective Randomized Trial Comparing Sirolimus-Coated Balloon With Paclitaxel-Coated Balloon in De Novo Small Vessels. *JACC: Cardiovascular Interventions.*;0. doi:10.1016/j.jcin.2023.09.026.

39. Spaulding C, Krackhardt F, Bogaerts K, Urban P, Meis S, Morice M-C, Eccleshall S. Comparing a strategy of sirolimus-eluting balloon treatment to drug-eluting stent implantation in de novo coronary lesions in all-comers: Design and rationale of the SELUTION DeNovo Trial. *American Heart Journal*. 2023;258:77–84.

40. Greco A, Sciahbasi A, Abizaid A, Mehran R, Rigattieri S, de la Torre Hernandez JM, Alfonso F, Cortese B. Sirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial. *Catheterization and Cardiovascular Interventions*. 2022;100:544–552.

Figures and Tables legends

Figure 1. Evidence search and selection of Preferred Reporting Items for Systematic Reviews

and Meta-Analyses (PRISMA).




Figure 2. Forest plots comparing Cardiovascular Death between Drug Coated Balloon Versus Drug

Eluting Stent.

	DCE	3	DES	5		Risk Ratio	Risk Ratio
Study or Subgroup	Events Total		Events Total		Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Gitto et al. 2023	0	139	7	139	6.9%	0.07 [0.00, 1.16]	
Gobic' et al. 2017	0	38	0	37		Not estimable	
Gunawardena et al. 2023	2	41	7	107	24.0%	0.75 [0.16, 3.44]	
Her et al. 2018	0	78	1	73	5.5%	0.31 [0.01, 7.54]	· · · · · · · · · · · · · · · · · · ·
lwasaki et al. 2020	0	69	0	88		Not estimable	
Nakamura et al. 2022	3	73	9	81	35.0%	0.37 [0.10, 1.31]	
Nijhoff et al. 2015	0	40	0	49		Not estimable	
Nishiyama et al. 2016	0	27	0	33		Not estimable	
Scheller et al. 2019	3	85	3	51	23.0%	0.60 [0.13, 2.86]	
Vos et al. 2019	0	59	0	61		Not estimable	
Xiaojiao Hao et al. 2021	1	38	0	42	5.6%	3.31 [0.14, 78.84]	
Xue Yu et al. 2021	0	84	0	79		Not estimable	
Total (95% CI)		771		840	100.0%	0.49 [0.23, 1.03]	•
Total events	9		27				
Heterogeneity: Tau ² = 0.00;	$Chi^2 = 4.0$)3, df=	5 (P = 0.9	55); I ² =	0%		
Test for overall effect: Z = 1.			2				0.001 0.1 1 10 1000 Favours [DCB] Favours [DES]

Figure 3. Forest plots comparing Myocardial Infarction between Drug Coated Balloon Versus Drug **Eluting Stent.**

	DCE	3	DES	5		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events Total		Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Gitto et al. 2023	0	139	1	139	11.9%	0.33 [0.01, 8.11]	
Gobic' et al. 2017	2	38	2	37	33.2%	0.97 [0.14, 6.56]	+
Gunawardena et al. 2023	0	41	7	107	15.0%	0.17 [0.01, 2.94]	
Her et al. 2018	0	78	0	73		Not estimable	
lwasaki et al. 2020	0	69	0	88		Not estimable	
Nakamura et al. 2022	0	73	0	81		Not estimable	
Nijhoff et al. 2015	0	40	0	49		Not estimable	
Nishiyama et al. 2016	0	27	0	33		Not estimable	
Scheller et al. 2019	0	85	1	51	11.9%	0.20 [0.01, 4.86]	· · · · · ·
Vos et al. 2019	0	59	0	61		Not estimable	
Xiaojiao Hao et al. 2021	0	38	1	42	12.0%	0.37 [0.02, 8.76]	
Xue Yu et al. 2021	1	84	1	79	15.9%	0.94 [0.06, 14.78]	
Total (95% CI)		771		840	100.0%	0.48 [0.16, 1.45]	•
Total events	3		13				
Heterogeneity: Tau ² = 0.00;	Chi ² = 1.6	69, df =	5 (P = 0.)	89); I ^z =	0%		
Test for overall effect: Z = 1.	.29 (P = 0.	20)	2				0.001 0.1 1 10 1000 Favours [DCB] Favours [DES]

Figure 4. Forest plots comparing Target Lesion Revascularization between Drug Coated Balloon Versus Drug Eluting Stent.

	DCE	3	DES	;		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Gitto et al. 2023	4	139	16	139	17.0%	0.25 [0.09, 0.73]	
Gobic' et al. 2017	0	38	0	37		Not estimable	
Gunawardena et al. 2023	3	41	9	107	14.2%	0.87 [0.25, 3.05]	
Her et al. 2018	1	78	3	73	6.1%	0.31 [0.03, 2.93]	
lwasaki et al. 2020	6	69	4	88	14.6%	1.91 [0.56, 6.51]	
Nakamura et al. 2022	5	73	12	81	18.4%	0.46 [0.17, 1.25]	
Nijhoff et al. 2015	5	40	1	49	6.7%	6.13 [0.75, 50.32]	+
Nishiyama et al. 2016	0	27	2	33	3.7%	0.24 [0.01, 4.85]	
Scheller et al. 2019	1	85	0	51	3.3%	1.81 [0.08, 43.71]	
Vos et al. 2019	2	59	1	61	5.5%	2.07 [0.19, 22.20]	
Xiaojiao Hao et al. 2021	1	38	1	42	4.3%	1.11 [0.07, 17.06]	
Xue Yu et al. 2021	1	84	3	79	6.1%	0.31 [0.03, 2.95]	
Total (95% CI)		771		840	100.0%	0.73 [0.40, 1.34]	•
Total events	29		52				
Heterogeneity: Tau ² = 0.26;	Chi ² = 13	.71, df=	= 10 (P =	0.19); [² = 27%		
Test for overall effect: Z = 1.0	00 (P = 0.	32)					0.001 0.1 1 10 1000 Favours [DCB] Favours [DES]

Figure 5. Forest plots comparing All Cause Death between Drug Coated Balloon Versus Drug Eluting Stent.

	DCE	3	DES	5		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Gitto et al. 2023	5	139	7	139	7.8%	0.71 [0.23, 2.20]	
Gunawardena et al. 2023	8	41	16	107	16.7%	1.30 [0.61, 2.81]	
lwasaki et al. 2020	0	69	0	88		Not estimable	
Merinopoulos et al. 2022	35	544	59	693	60.7%	0.76 [0.51, 1.13]	=
Nakamura et al. 2022	4	73	12	81	8.3%	0.37 [0.12, 1.10]	
Nijhoff et al. 2015	1	40	0	49	1.0%	3.66 [0.15, 87.44]	
Nishiyama et al. 2016	0	27	0	33		Not estimable	
Scheller et al. 2019	4	85	4	51	5.5%	0.60 [0.16, 2.30]	
Total (95% CI)		1018		1241	100.0%	0.78 [0.57, 1.07]	•
Total events	57		98				
Heterogeneity: Tau ² = 0.00;	Chi ² = 4.6	65, df =	5 (P = 0.4	46); I ² =	0%		
Test for overall effect: Z = 1.9	56 (P = 0.	12)	19				0.001 0.1 1 10 1000 Favours [DCB] Favours [DES]

Figure 6. Forest plots comparing Late Lumen Loss between Drug Coated Balloon Versus Drug Eluting Stent.

		DCB			DES			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Gobic' et al. 2017	0.1	0.19	38	-0.09	0.09	37	12.3%	0.19 [0.12, 0.26]	· •
Her et al. 2018	0.05	0.33	78	0.59	0.76	73	10.7%	-0.54 [-0.73, -0.35]	
lwasaki et al. 2020	0.31	0.67	69	0.29	0.6	88	10.5%	0.02 [-0.18, 0.22]	
Nakamura et al. 2022	0.133	0.5	73	0.46	0.78	81	10.5%	-0.33 [-0.53, -0.12]	
Nijhoff et al. 2015	0.13	0.33	40	0.16	0.43	49	11.2%	-0.03 [-0.19, 0.13]	
Nishiyama et al. 2016	0.25	0.25	27	0.37	0.4	33	11.1%	-0.12 [-0.29, 0.05]	
Vos et al. 2019	-0.05	0.46	59	-0.02	0.2	61	11.7%	-0.03 [-0.16, 0.10]	
Xiaojiao Hao et al. 2021	-0.11	0.45	38	0.13	0.3	42	11.0%	-0.24 [-0.41, -0.07]	
Xue Yu et al. 2021	-0.19	0.49	84	0.03	0.64	79	10.9%	-0.22 [-0.40, -0.04]	
Total (95% CI)			506			543	100.0%	-0.14 [-0.30, 0.02]	•
Heterogeneity: Tau ² = 0.0	5; Chi ² =	88.05	df = 8	(P < 0.0	0001);	I ² = 91	%		
Test for overall effect: Z =	1.66 (P =	0.10)		2					-1 -0.5 0 0.5 1
	<u>i</u> ()	1							Favours [DES] Favours [DCB]

Figure 7. Forest plots comparing Minimal lumen diameter before and after procedure between Drug **Coated Balloon Versus Drug Eluting Stent.**

	After	proced	ure	Before	proced	lure		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.8.1 DCB									
Her et al. 2018	2.03	0.41	78	0.7	0.51	78	17.0%	1.33 [1.18, 1.48]	+
lwasaki et al. 2020	2.39	0.56	80	1.35	0.49	80	16.8%	1.04 [0.88, 1.20]	-
Nakamura et al. 2022	2.35	0.48	73	1.18	0.33	73	17.1%	1.17 [1.04, 1.30]	· · · · · · · · · · · · · · · · · · ·
Nijhoff et al. 2015	2.22	0.45	40	0.29	0.5	40	16.2%	1.93 [1.72, 2.14]	+
Nishiyama et al. 2016	2.36	0.46	27	0.73	0.38	27	16.0%	1.63 [1.40, 1.86]	-
Xue Yu et al. 2021	1.82	0.43	84	1.01	0.55	84	16.9%	0.81 [0.66, 0.96]	+
Subtotal (95% CI)			382			382	100.0%	1.31 [1.02, 1.60]	•
Heterogeneity: Tau ² = 0.	.12; Chi ²	= 93.68	6, df = 5	(P < 0.00	0001); P	= 95%			
Test for overall effect: Z	= 8.85 (P	< 0.00	001)						
1.8.2 DES									
Her et al. 2018	2.8	0.51	73	0.59	0.48	73	16.5%	2.21 [2.05, 2.37]	+
lwasaki et al. 2020	3.01	0.26	104	1.29	0.49	104	17.5%	1.72 [1.61, 1.83]	-
Nakamura et al. 2022	2.88	0.37	81	0.94	0.51	81	16.9%	1.94 [1.80, 2.08]	+
Nijhoff et al. 2015	2.53	0.41	49	0.34	0.41	49	16.4%	2.19 [2.03, 2.35]	+
Nishiyama et al. 2016	2.64	0.37	33	0.61	0.31	33	16.4%	2.03 [1.87, 2.19]	+
Xue Yu et al. 2021	2.54	0.5	79	1.01	0.59	79	16.3%	1.53 [1.36, 1.70]	+
Subtotal (95% CI)			419			419	100.0%	1.94 [1.73, 2.14]	•
Heterogeneity: Tau ² = 0.	.06; Chi ²	= 58.29	9, df = 5	(P < 0.0)	0001); l ^a	= 91%			
Test for overall effect: Z	•		•						
		6	í.						
									-2 -1 0 1 2
Test for subgroup differ	oncos: C	hi ² – 11	QA df	- 1 (P - 1	/a000.0	IZ - Q1	696		Before procedure After procedure

Test for subgroup differences: Chi² = 11.84, df = 1 (P = 0.0006), l² = 91.6%

All rights reserved. No reuse allowed without permission.

Figure 8. Forest plots comparing Cardiovascular Death (A), Myocardial Infarction (B), Target Lesion Revascularization (C), All Cause Death (D) and Late Lumen Loss (E) between Drug Coated Balloon Versus Drug Eluting Stent in randomized controlled trials subgruoup.




Figure 9. Forest plots comparing Minimal Lumen Diameter before and after the procedure between Drug Coated Balloon Versus Drug Eluting Stent in randomized controlled trials subgruoup.

	After	proced	ure	Before	proced	lure		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
2.8.1 DCB									
Nishiyama et al. 2016	2.36	0.46	27	0.73	0.38	27	30.6%	1.63 [1.40, 1.86]	
Xue Yu et al. 2021	1.82	0.43	84	1.01	0.55	84	69.4%	0.81 [0.66, 0.96]	
Subtotal (95% CI)			111			111	100.0%	1.06 [0.94, 1.18]	•
Heterogeneity: Chi ² = 35	5.41, df =	1 (P <)	0.00001); I ^z = 97	%				
Test for overall effect: Z	= 16.71 (P < 0.0	0001)						
2.8.2 DES									
						~~	F4 700		
Nishiyama et al. 2016	2.64	0.37	33	0.61	0.31	33		2.03 [1.87, 2.19]	
Xue Yu et al. 2021	2.54	0.5	79	1.01	0.59	79	48.3%	1.53 [1.36, 1.70]	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)			112			112	100.0%	1.79 [1.67, 1.91]	•
Heterogeneity: Chi ² = 17	7.09, df =	1 (P < I	0.0001)	; I ² = 949	6				
Test for overall effect: Z	= 29.59 (P < 0.0	0001)						
								_	
									-2 -1 0 1 2
Test for subgroup differ		1		4 (5)			0.00		Before procedure After procedure

Test for subgroup differences: Chi² = 69.01, df = 1 (P < 0.00001), I² = 98.6%

Author		Nijhoff et al	Nishiyama et al	Gobic et al	Her et al	Vos et al	Scheller et al	Iwasaki et al	Xue Yu et al	Xiaojia o Hao et al	Merinopoulo s et al	Nakamura et al	Gunawarden a T.D. et al	Gitto et al
Year		2015	2016	2017	2018	2019	2019	2020	2021	2021	2022	2023	2023	2023
Study type		Nonrandomized , single-center (arm of the Randomized DEB-AMI Trial)	A Simple- Randomization , Open-label, Single-Center	RCT	Prospective, observationa l Registry, Single center	RCT (The REVELATIONI)	RCT (The PEPCAD NSTEMI)	Retrospective, single-center, nonrandomize d	RCT	RCT	Retrospective, single-center, nonrandomized	Retrospective, single-center, nonrandomize d	Retrospective, single-center, nonrandomized	Retrospective, 2-center, nonrandomize d
Total patients, n		40	60	75	151	120	210	165	170	80	1237	154	148	278
DCB patients, n		40	27	38	78	59	104	69	84	38	544	73	41	139
DES patients, n		49	33	37	73	61	51	88	79	42	693	81	107	139
Primary endpoi	nt	LLL	MLD, LLL	MACE, LLL	LLL	MLD, LLL	TLF (Cardiac death, Unknown death, MI, TLR)	MACE	LLL, MACE	LLL	All-cause death	Cardiac death, MI, TLR	All-cause death	TLF (Cardiac Death, MI, TLR)
Definition of MA	ACE	Cardiac death, MI, TLR	Cardiac death, MI, TLR	Cardiac death, MI, TLR	Cardiac death, MI, TLR, TVR	Cardiac death, MI, TLR	Cardiac death, Non-cardiac death, MI, TLR, Stroke, PCI At Other Vessels	Cardiac death, Non-cardiac death, MI, TLR, Major bleeding	Cardiac death, MI, TLR	Cardiac death, MI, TLR	Cardiac death, MI, TLR	Cardiac death, MI, TLR	Cardiac death, MI, TLR	Cardiac Death, Non- Cardiac Death, MI, TLR
A ()	DCB	57.9+10.0	67.30+11.12	54.3±10.6	58.6±8.6	57.4+9.2	66±11.4	76±7.2	62.6±8.8	59±11	69 (61-75)	67.1±11.4	73.8±11.7	69.32±10.22
Age (years)	DES	55.9+9.7	70.63+8.97	57.2±13.1	59.0±8.7	57.3+8.3	67±13.1	74±8.4	64.0±10.5	56±11	69 (61-75)	69.0±10.4	69.8±1.1	69.13±11.72
Clinical presentation	DCB	40 (100) / 0	27 (100) / 0	38 (100) / 0	40 (51.3) / 38 (48.7)	59 (100) / 0	104 (100) / 0	2 (2) / 67 (98)	76 (90.5) / 8 (9.5)	38 (100) / 0	0 / 544 (100)	0 / 73 (100)	28 (68.3) / 13 (31.7)	0 / 139 (100)
ACS/CCS, n (%)	DES	49 (100) / 0	33 (100) / 0	37 (100) / 0	44 (60.3) / 29 (39.7)	61 (100) / 0	51 (100) / 0	2 (2) / 86 (98)	69 (87.4) / 10 (12.7)	42 (100) / 0	0 / 693 (100)	0 / 81 (100)	57 (53.2) / 50 (46.7)	0 / 139 (100)
Diabetes	DCB	5 (12.5)	12 (40.0)	4 (10.8)	25 (32.1)	8 (13)	28 (26.9)	37 (54)	16 (19.0)	10 (28)	125 (23)	36 (49.3)	13 (31.7)	44 (31.65)
mellitus, n (%)	DES	2 (4.1)	13 (43.3)	2 (5.3)	16 (21.9)	4 (7)	38 (35.8)	41 (47)	23 (29.1)	15 (35)	153 (22)	40 (49.4)	24 (22.4)	32 (23.02)
CLUB	DCB	N/A	2 (6.7)	0	N/A	N/A	N/A	17 (19)	N/A	N/A	N/A	11 (15.1)	N/A	14 (10.07)
CKD	DES	N/A	4 (13.3)	2 (5.3)	N/A	N/A	N/A	6 (9)	N/A	N/A	N/A	13 (16.0)	N/A	8 (5.76)
Target I M	DCB	N/A	N/A	N/A	N/A	N/A	N/A	2 (2)	N/A	N/A	15 (2.8)	1 (1.8)	148 (100)	0
Lesion Livi	DES	N/A	N/A	N/A	N/A	N/A	N/A	3 (3)	N/A	N/A	27 (3.9)	3 (3.8)	0	0

Table 1. Main Features of the Studies Included in the Meta-Analysis

LAD	DCB	18 (45)	12 (44)	N/A	35 (44.9)	19 (32)	51 (41.5)	47 (59)	48 (57.1)	19 (52)	309 (57)	23 (32.1)	0	139 (100)
LAD	DES	18 (37)	17 (51.5)	N/A	42 (57.5)	24 (40)	46 (38.3)	62 (60)	35 (44.3)	22 (50)	376 (54)	29 (35.8)	0	139 (100)
	DCB	2.83±0.51	2.88±0.57	3.04±0.46	2.6±0.5	3.28±0.52	N/A	2.97±0.45	2.77 (2.50 to 3.25)	N/A	3.00 (2.75– 3.50)	2.97±0.42	3.84±0.26	3.12 (0.48)
RVD, mm	DES	2.78±0.53	2.72±0.64	2.61±0.49	3.1±0.5	3.20±0.48	N/A	3.03±0.36	3.01 (2.65 to 3.39)	N/A	3.50 (3.00– 3.75)	3.32±0.42	4.33±0.60	3.09 (0.35)
Lesion Length,	DCB	13.0±5.7	16.13±5.25	N/A	20.0±5.4	N/A	N/A	14.3±7.3	18.2 (16.0 to 20.1)	N/A	20 (20–30)	N/A	21.71±7.80	65 (40-82)
mm	DES	16.8±8.7	18.14±7.41	N/A	21.7±6.4	N/A	N/A	19±10	20.0 (15.0 to 25.0)	N/A	24 (18–38)	N/A	24.72±14.32	53 (45-62)
DCB drug		Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel	Paclitaxel and Sirolimus
DCB brand		Dior	Sequent Please	Sequent Please	Sequent Please	Pantera Lux	Sequent Please	Sequent Please	Sequent Please	Biotech Bingo	N/A	Sequent Please	Sequent Please Neo	Magic Touch, Selution, In- Pact/Prevail, Restore
DES brand		N/A	Xience Prime, Xience Xpedition	Cobalt- Chromiu m Sirolimus Biomime	Resolute Integrity, Xience Prime	Orsiro	N/A	N/A	Resolute, Synergy, Xience	N/A	N/A	Ultimaster, Synergy, Ultimaster Tansei, Xience Alpine/Sierra, Promus Promier, Resolute Integrity	Resolute Onyx, Promus Premier, Synergy, Xience, Promus Element, Ultimaster	N/A
Lesion preparatio Strategy	on	Thrombus aspiration and SC ballon pre- dilatation	Scoring balloon pre- dilatation	Thrombus aspiration and SC balloon pre- dilation or both	SC ballon pre- Dilatation	Thrombus aspiration and SC ballon pre- Dilatation	According to the DCB Consensus Group	Mandatory rotablation, according to the Study Design and SC ballon pre- dilatation	According to the recommendation s of the German and Chinese consensus group. NC, cutting, scoring or NSE balloons	SC ballon pre- dilatation	SC ballon pre- dilatation	SC or Scoring Balloon Pre- Dilation	According to the third DCB consensus group	Balloons with a balloon-to- vessel ratio of 1:1, cutting balloons, or atherectomy devices
Clinical follow-uj months	p,	12	8	6	12	9	9	12	12	12	42	14	33	24
Angiographic follow-up, months		12	8	6	9	9	N/A	12	9	12	N/A	14	N/A	N/A

RCT: randomized controlled trial; DCB drug coated balloon, DES drug eluting stent, RVD reference vessel diameter, LLL late lumen loss, MLD minimum lumen diameter, MACE major adverse cardiovascular eventes, MI myoacardial infarction, NC non-compliant, SC semi-compliant, NSE non-slip element, TLF target lesion failure, TLR target lesion revascularization, ACS acute coronary syndrome, CCS chronic coronary syndrome, CKD chronic kidney disease, LM left main, LAD left anterior descending, LCX left cirrunflex, RCA right coronary artery.